User profiles for H. Chertkow

Howard Chertkow

Senior Scientist and Chair of Cognitive Neurology and Innovation, Baycrest Health Sciences …
Verified email at research.baycrest.org
Cited by 62372

Mild cognitive impairment

…, S Belleville, H Brodaty, D Bennett, H Chertkow… - The lancet, 2006 - thelancet.com
Mild cognitive impairment is a syndrome defined as cognitive decline greater than expected
for an individual's age and education level but that does not interfere notably with activities …

Diagnosis and treatment of dementia: 2. Diagnosis

…, HM Schipper, M Blair, A Kertesz, H Chertkow - Cmaj, 2008 - Can Med Assoc
Background: Dementia can now be accurately diagnosed through clinical evaluation,
cognitive screening, basic laboratory evaluation and structural imaging. A large number of …

Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia

H Chertkow, F Massoud, Z Nasreddine, S Belleville… - Cmaj, 2008 - Can Med Assoc
… Competing interests: Howard Chertkow has served on the … Howard Chertkow is the senior
author and Ziad Nasreddine is … Chertkow H. High and low tech prediction of progression to …

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic …

GM McKhann, DS Knopman, H Chertkow… - Alzheimer's & …, 2011 - Elsevier
The National Institute on Aging and the Alzheimer’s Association charged a workgroup with
the task of revising the 1984 criteria for Alzheimer’s disease (AD) dementia. The workgroup …

The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment

…, I Collin, JL Cummings, H Chertkow - Journal of the …, 2005 - Wiley Online Library
… Howard Chertkow MD … Howard Chertkow MD … Chertkow is a national researcher of
the Fonds de la recherche en Santé du Québec. Dr. Jeffrey L. …

Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial

…, A Carrasco, JC Yepez, E Chavez, H Chertkow… - Jama, 2023 - jamanetwork.com
Importance There are limited efficacious treatments for Alzheimer disease. Objective To assess
efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid …

Semantic memory loss in dementia of Alzheimer's type: What do various measures measure?

H Chertkow, D Bub - Brain, 1990 - academic.oup.com
… In patients who have had both naming and lexical decision tested, however, the pattern of
results has been similar for the two tasks (H. Chertkow, D. Bub and A. Bruemmer, unpublished …

World‐Wide FINGERS Network: a global approach to risk reduction and prevention of dementia

…, P Caramelli, C Chen, H Chertkow… - Alzheimer's & …, 2020 - Wiley Online Library
Reducing the risk of dementia can halt the worldwide increase of affected people. The
multifactorial and heterogeneous nature of late‐onset dementia, including Alzheimer's disease (…

Working memory and control of attention in persons with Alzheimer's disease and mild cognitive impairment.

S Belleville, H Chertkow, S Gauthier - Neuropsychology, 2007 - psycnet.apa.org
The goal of the present study was to assess 3 attentional control processes--divided attention,
manipulation capacities, and inhibition--in persons with mild cognitive impairment (MCI) …

Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer's disease

V Singh, H Chertkow, JP Lerch, AC Evans, AE Dorr… - Brain, 2006 - academic.oup.com
Cortical thickness is a more reliable measure of atrophy than volume due to the low variability
in the cytoarchitectural structure of the grey matter. However, this more desirable measure …